As hypoxia upregulates PD-L1, declining tumor hypoxia during treatment could lead to reduced tumoral PD-L1 expression and could abrogate the PD-1/PD-L1 immune suppression pathway, leading to improved anti-tumor activity of tumor-infiltrating lymphocytes 51. The gene discussed is CD274; the disease is neoplasm.